The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tocilizumab in combination with ipilimumab and nivolumab in solid tumors.
 
Noha Abdel-Wahab
Honoraria - ChemoCentryx
Consulting or Advisory Role - ChemoCentryx
 
Emma Montazari
No Relationships to Disclose
 
Christine Spillson
No Relationships to Disclose
 
Salah-Eddine Bentebibel
No Relationships to Disclose
 
Muhammad Awiwi
No Relationships to Disclose
 
Khaled M. Elsayes
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)
Travel, Accommodations, Expenses - Nektar
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Pfizer; Regeneron
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Iovance Biotherapeutics; Nektar; Novartis; Obsidian Therapeutics
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb/Roche; Merck
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Immunocore; Merck
Consulting or Advisory Role - Castle Biosciences; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - TriSalus Life Sciences
Other Relationship - Immunocore
 
Hussein A. Tawbi
Consulting or Advisory Role - Array BioPharma; Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; NanoString Technologies; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Cassian Yee
No Relationships to Disclose
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Inimmune; InterVenn Biosciences; InterVenn Biosciences (I); Jounce Therapeutics; Jounce Therapeutics (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
James Patrick Allison
No Relationships to Disclose
 
Suhendan Ekmekcioglu
No Relationships to Disclose
 
Adi Diab
No Relationships to Disclose